OctoPlus signs drug delivery feasibility deal
OctoPlus has inked a deal with a European biotech that will see it evaluate the feasibility of a controlled release formulation using its proprietary drug delivery technology.
The European biotech, which is not being named by OctoPlus, will become the seventh company that the drug delivery specialist has worked on a controlled release formulation for.
Under the terms of the latest agreement OctoPlus will asses the feasibility of creating a formulation of the client’s active pharmaceutical ingredient (API) using its drug delivery technology.
If the evaluation deems that a formulation could be created the contract may be extended to become a full process development, manufacturing and licensing agreement.
